Focused On-demand Library for Intraflagellar transport protein 81 homolog

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q8WYA0

UPID:
IFT81_HUMAN

ALTERNATIVE NAMES:
Carnitine deficiency-associated protein expressed in ventricle 1

ALTERNATIVE UPACC:
Q8WYA0; Q2YDY1; Q8NB51; Q9BSV2; Q9UNY8

BACKGROUND:
The Intraflagellar transport protein 81 homolog, known alternatively as Carnitine deficiency-associated protein expressed in ventricle 1, is integral to the intraflagellar transport (IFT) complex B. It binds tubulin and is indispensable for ciliogenesis and SHH signaling regulation. Its role extends to reproductive health, influencing spermatogenesis by affecting sperm flagella assembly and elongation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Short-rib thoracic dysplasia 19, IFT81 represents a promising target for therapeutic intervention. Exploring IFT81's function further could unveil novel approaches to manage and potentially treat a spectrum of ciliopathies, offering hope for patients with these challenging conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 899 of 8789